US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Zentalis Pharmaceuticals, Inc. - common stock (NQ:ZNTL)

2.670 -0.110 (-3.96%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zentalis Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 Next >
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Q1 2026 EPS Matches Estimates, Stock Flat ↗
Via Chartmill
News headline image
Which stocks are experiencing notable movement on Friday? ↗
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Topics Artificial Intelligence
News headline image
What's Behind The Surge In Zentalis Stock? ↗
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) shares are surging Friday after a Guggenheim analyst raised the price target from $6 to $10. 
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Topics Artificial Intelligence
News headline image
(ZNTL) - Analyzing Zentalis Pharma's Short Interest ↗
 
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Reports Q3 2025 Earnings Beat Amidst Stock Decline ↗
Zentalis (ZNTL) beat Q3 2025 earnings estimates. The biotech firm has no revenue but a strong cash position, with key data for its lead drug, azenosertib, expected in late 2026. 
Via Chartmill
Topics Earnings
News headline image
Zentalis (ZNTL) Q2 Loss Narrows 70% ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Here are the top movers in Wednesday's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
These stocks that are showing activity before the opening bell on Wednesday. ↗
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers ↗
The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies. Zentalis plans to work with trial investigators to continue development while presenting additional data... 
Via Benzinga
News headline image
Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL
From Newman Ferrara LLP
Via Business Wire
News headline image
Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
ZNTL Stock Earnings: Zentalis Pharma Misses EPS for Q2 2024 ↗
ZNTL stock results show that Zentalis Pharma missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
ZNTL Investors Have Opportunity to Join Zentalis Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22 ↗
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024. 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday? ↗
Zentalis Pharmaceuticals announced the FDA's partial clinical hold on azenosertib studies due to recent patient deaths. 
Via Benzinga
< Previous 1 2 3 4 Next >